1
|
Aubin HJ, Berlin I, Guiraud J, Bruhwyler J, Batel P, Perney P, Trojak B, Bendimerad P, Guillou M, Bisch M, Grall-Bronnec M, Labarrière D, Delsart D, Questel F, Moirand R, Bernard P, Trovero F, Pham HP, Tassin JP, Puech A. Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial. Addiction 2024. [PMID: 38597214 DOI: 10.1111/add.16484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Accepted: 02/23/2024] [Indexed: 04/11/2024]
Abstract
BACKGROUND AND AIMS Pre-clinical studies suggest that the simultaneous blockade of the α1b and 5HT2A receptors may be effective in reducing alcohol consumption. This study aimed to assess the efficacy and safety of prazosin (α1b blocker) and cyproheptadine (5HT2A blocker) combination in decreasing total alcohol consumption (TAC) in alcohol use disorder (AUD). DESIGN, SETTING AND PARTICIPANTS This was a double-blind, parallel group, placebo-controlled, Phase 2, randomized clinical trial conducted in 32 addiction treatment centres in France. A total of 108 men and 46 women with severe AUD took part. INTERVENTION Participants were randomly assigned to one of the following 3-month treatments: (1) low-dose group (LDG) receiving 8 mg cyproheptadine and 5 mg prazosin extended-release (ER) formulation daily; (2) high-dose group (HDG) receiving 12 mg cyproheptadine and 10 mg prazosin ER daily; and (3) placebo group (PG) receiving placebo of cyproheptadine and prazosin ER. A total of 154 patients were randomized: 54 in the PG, 54 in the LDG and 46 in the HDG. MEASUREMENTS The primary outcome was TAC change from baseline to month 3. FINDINGS A significant main treatment effect in the change in TAC was found in the intent-to-treat population (P = 0.039). The HDG and LDG showed a benefit in the change in TAC from baseline to month 3 compared with PG: -23.6 g/day, P = 0.016, Cohen's d = -0.44; -18.4 g/day, P = 0.048 (Bonferroni correction P < 0.025), Cohen's d = -0.36. In a subgroup of very high-risk drinking-level participants (> 100 g/day of pure alcohol for men and > 60 g/day for women), the difference between the HDG and the PG in the primary outcome was -29.8 g/day (P = 0.031, Cohen's d = -0.51). The high and low doses were well-tolerated with a similar safety profile. CONCLUSIONS A randomized controlled trial of treatment of severe alcohol use disorder with a cyproheptadine-prazosin combination for 3 months reduced drinking by more than 23 g per day compared with placebo. A higher dose combination was associated with a larger magnitude of drinking reduction than a lower dose combination while showing similar safety profile.
Collapse
Affiliation(s)
| | - Ivan Berlin
- Hopital Pitie-Salpetriere, Sorbonne Université, Paris, France
| | - Julien Guiraud
- University of Amsterdam, Amsterdam, the Netherlands
- Vergio, Clichy, France
| | | | | | - Pascal Perney
- Hôpital Carémeau, Nîmes, Université Montpellier 1, Villejuif, France
| | - Benoît Trojak
- Centre hospitalier Universitaire Dijon Bourgogne, Université Bourgogne Franche-Comté, Besançon, France
| | - Patrick Bendimerad
- Addiction Department, Groupe Hospitalier Littoral Atlantique, La Rochelle, France
| | - Morgane Guillou
- ER 7479 SPURBO, Université Bretagne Occidentale, Brest, France
| | - Michaël Bisch
- Centre Psychothérapique de Nancy, Addiction Medicine department, Laxou, France
| | - Marie Grall-Bronnec
- Addictology and Liaison Psychiatry Department, Nantes University Hospital, Nantes and Tours Universities, Nantes, France
| | | | | | - Frank Questel
- Université Paris Diderot, GH Lariboisière-Saint-Louis-Fernand Widal, Paris, France
| | - Romain Moirand
- Université Rennes, Rennes, Institut NUMECAN (Nutrition Metabolisms and Cancer), UF Addictologie, Rennes, France
| | | | | | | | - Jean-Pol Tassin
- Inserm, Sorbonne-Université, Laboratoire Neuroscience Paris-Seine, Paris, France
| | - Alain Puech
- Kinnov-Therapeutics, Orléans, France
- Inserm, Sorbonne-Université, Laboratoire Neuroscience Paris-Seine, Paris, France
| |
Collapse
|